Mc2 Therapeutics

Mc2 Therapeutics company information, Employees & Contact Information

Explore related pages

Related company profiles:

MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. We believe in restoring dignity and freedom to patients. We believe in therapies that are designed to integrate seamlessly into people’s daily routines, offering confidence without compromise. Our marketed flagship drug Wynzora® Cream is more than a drug; it’s a lifelong partner in reclaiming the simplicity and ease of every day for people with plaque psoriasis. Wynzora® is partnered with leading pharmaceutical companies specialized in dermatology covering more than 40 countries in four continents representing more than 2.6 billion people. This page is not intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about MC2 Therapeutics and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Please keep in mind that MC2 Therapeutics work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of MC2 Therapeutics.

Company Details

Employees
22
Founded
-
Address
Agern Alle 24-26, Hørsholm,2970,denmark
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Hørsholm
Looking for a particular Mc2 Therapeutics employee's phone or email?

Mc2 Therapeutics Questions

News

FDA approves plaque psoriasis topical - Dermatology Times

FDA approves plaque psoriasis topical Dermatology Times

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics - PR Newswire

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics PR Newswire

NDA for Plaque Psoriasis Treatment Wynzora Submitted for Review - Medical Professionals Reference

NDA for Plaque Psoriasis Treatment Wynzora Submitted for Review Medical Professionals Reference

MC2 Therapeutics appoints Trine Ahlgreen as new CEO - Pharmafile

MC2 Therapeutics appoints Trine Ahlgreen as new CEO Pharmafile

Psoriasis cream safe, effective suggests EU phase 3 results - Dermatology Times

Psoriasis cream safe, effective suggests EU phase 3 results Dermatology Times

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada - PR Newswire

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada PR Newswire

MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora ® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone (as dipropionate)) - NTB Kommunikasjon

MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora ® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone (as dipropionate)) NTB Kommunikasjon

Top Mc2 Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant